The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Effects of Sho–Saiko–To, A Japanese Herbal Medicine, on Hepatic Fibrosis in Rats
Abstract
It has been shown that lipid peroxidation is associated with hepatic fibrosis and stellate cell activation. Sho–saiko–to (TJ–9) is an herbal medicine, which is commonly used to treat chronic hepatitis in Japan, although the mechanism by which TJ–9 protects against hepatic fibrosis is not known. As a result, we assayed the preventive and therapeutic effects of TJ–9 on experimental hepatic fibrosis, induced in rats by dimethylnitrosamine (DMN) or pig serum (PS), and on rat stellate cells and hepatocytes in primary culture, and assessed the antioxidative activities and the active components of TJ–9. Male Wistar rats were given a single intraperitoneal injection of 40 mg/kg DMN or 0.5 mL PS twice weekly for 10 weeks. In each model, rats were fed a basal diet throughout, or the same diet, which also contained 1.5% TJ–9, for 2 weeks before treatment or for the last 2 weeks of treatment. TJ–9 suppressed the induction of hepatic fibrosis, increased hepatic retinoids, and reduced the hepatic levels of collagen and malondialdehyde (MDA), a production of lipid peroxidation. Immunohistochemical examination showed that TJ–9 reduced the deposition of type I collagen and the number of α–smooth muscle actin (α–SMA) positive–stellate cells in the liver and inhibited, not only lipid peroxidation in cultured rat hepatocytes that were undergoing oxidative stress, but also the production of type I collagen, α–SMA expression, cell proliferation, and oxidative burst in cultured rat stellate cells. In addition, TJ–9 inhibited Fe 2+/adenosine 5′–diphosphate–induced lipid peroxidation in rat liver mitochondria in a dose–dependent manner and showed radical scavenging activity. Among the active components of TJ–9, baicalin and baicalein were found to be mainly responsible for the antioxidative activity. These findings suggest that Sho–saiko–to (TJ–9) functions as a potent antifibrosuppressant by inhibition of lipid peroxidation in hepatocytes and stellate cells in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McCord, J. M., & Fridovich, I. (1969) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)63504-5 · Cited by 12,952
Inhibition of Rat Hepatic Lipocyte Activation in Culture by Interferon–γ
Rockey, D. C., Maher, J. J., Jarnagin, W. R., Gabbiani, G., & Friedman, S. L. (1992) · Hepatology · doi:10.1002/hep.1840160325 · Cited by 179
Cited by
Liver fibrosis – from bench to bedside
Friedman, S. L. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00429-4 · Cited by 1,780
Omata, M., Lesmana, L. A., Tateishi, R., Chen, P.-J., Lin, S.-M., Yoshida, H., Kudo, M., Lee, J. M., Choi, B. I., Poon, R. T. P., et al. (2010) · Hepatology International · doi:10.1007/s12072-010-9165-7 · Cited by 1,026
Roles of TGF-beta in hepatic fibrosis
Gressner, A. M. (2002) · Frontiers in Bioscience · doi:10.2741/a812 · Cited by 783
Oxidative stress-related molecules and liver fibrosis
Parola, M., & Robino, G. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00142-8 · Cited by 783
Scutellaria baicalensis , the golden herb from the garden of Chinese medicinal plants
Zhao, Q., Chen, X.-Y., & Martin, C. (2016) · Science Bulletin · doi:10.1007/s11434-016-1136-5 · Cited by 541
Several Culinary and Medicinal Herbs Are Important Sources of Dietary Antioxidants
Dragland, S., Senoo, H., Wake, K., Holte, K., & Blomhoff, R. (2003) · The Journal of Nutrition · doi:10.1093/jn/133.5.1286 · Cited by 497
Zhao, T., Tang, H., Xie, L., Zheng, Y., Ma, Z., Sun, Q., & Li, X. (2019) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13129 · Cited by 478
Roles of TGF-beta in hepatic fibrosis
Gressner, A. (2002) · Frontiers in Bioscience · doi:10.2741/gressner · Cited by 405
Herbal medicine in the treatment of liver diseases
Stickel, F., & Schuppan, D. (2007) · Digestive and Liver Disease · doi:10.1016/j.dld.2006.11.004 · Cited by 364
Tsukada, S., Parsons, C. J., & Rippe, R. A. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2005.06.014 · Cited by 357
Liver fibrogenesis and the role of hepatic stellate cells: New insights and prospects for therapy
Li, D., & Friedman, S. (1999) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.1999.01928.x · Cited by 343
Hepatic fibrosis: molecular mechanisms and drug targets
Lotersztajn, S., Julien, B., Teixeira-Clerc, F., Grenard, P., & Mallat, A. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095906 · Cited by 325
The Global Impact of Hepatic Fibrosis and End-Stage Liver Disease
Lim, Y.-S., & Kim, W. R. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.07.007 · Cited by 316
Targeting Liver Fibrosis: Strategies for Development and Validation of Antifibrotic Therapies†
Popov, Y., & Schuppan, D. (2009) · Hepatology · doi:10.1002/hep.23123 · Cited by 296
Herbal products for liver diseases: A therapeutic challenge for the new millennium
Schuppan, D., Jia, J.-D., Brinkhaus, B., & Hahn, E. G. (1999) · Hepatology · doi:10.1002/hep.510300437 · Cited by 279
Hepatic stellate cells: a target for the treatment of liver fibrosis
Wu, J., & Zern, M. A. (2000) · Journal of Gastroenterology · doi:10.1007/s005350070045 · Cited by 273
Complementary and alternative medicine in chronic liver disease
Seeff, L. B., Lindsay, K. L., Bacon, B. R., Kresina, T. F., & Hoofnagle, J. H. (2001) · Hepatology · doi:10.1053/jhep.2001.27445 · Cited by 271
Impact of oestrogens on the progression of liver disease
Shimizu, I. (2003) · Liver International · doi:10.1034/j.1600-0676.2003.00811.x · Cited by 207
Self-citationAntifibrotic Agents for Liver Disease
Albanis, E., & Friedman, S. L. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.01143.x · Cited by 68
Metadata
- Authors
- Shimizu, I., Ma, Y.-R., Mizobuchi, Y., Liu, F., Miura, T., Nakai, Y., Yasuda, M., Shiba, M., Horie, T., Amagaya, S., Kawada, N., Hori, H., & Ito, S.
- Venue
- Hepatology
- Published
- 1999-01
- Volume
- 29
- Issue
- 1
- Pages
- 149-160
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2150071111
- Cited by
- 236
- References
- 2
- FWCI
- 8.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.